STOCKHOLM, Nov. 18, 2020
STOCKHOLM , Nov. 18, 2020 /PRNewswire/ -- "It is with great pleasure that we provide our first quarterly report since listing on Sweden's Nasdaq First North Premier Growth Market on 21 September."
- Peter Forsell, CEO and Founder of Implantica AG
Significant events during the third quarter, 2020
Significant events after the end of the reporting period
July - September 2020
January - September 2020
Implantica will hold a telephone conference on November 18 at 10:30 CET
To participate, please dial:
United Kingdom: +443333009260
United States: +18338230587
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, firstname.lastname@example.org
The information was sent for publication, through the agency of the contact person set out above, on November 18, 2020 at 08:00 a.m. CET.
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Interim Report January - September 2020
Implantica publishes Interim Report Q3 January-September 2020